Roche’s Polivy Set For Blockbuster Sales After Frontline Lymphoma Success

First Progress In Frontline DLBCL In 20 Years

Roche has not disclosed the full data yet, but is confident that Polivy can surpass CAR-Ts and other competitors to be the new standard of care.

Roche_Basel
While CAR-Ts grabbed the headlines when launched several years ago, Roche's Polivy looks set to have a greater impact on DLBCL treatment.

Roche’s Polivy in combination with chemotherapy could become the new standard first line therapy in diffuse large B-cell lymphoma (DLBCL) after significantly improving progression-free survival compared with standard treatment – the first time this has been achieved in 20 years.

The company announced the news from its Phase III POLARIX trial on 9 August, but revealed no further details. It...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip